PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8
Cytochrome P450, family 2, subfamily C, polypeptide 8 (CYP2C8) is a phase I metabolizing
enzyme that plays an integral role in the biotransformation of structurally diverse xenobiotics …
enzyme that plays an integral role in the biotransformation of structurally diverse xenobiotics …
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6
EM McDonagh, C Wassenaar, SP David… - Pharmacogenetics …, 2012 - journals.lww.com
Human cytochrome P-450 (CYP-450), family 2, subfamily A, polypeptide 6 (CYP2A6) is a
monooxygenase enzyme that metabolizes xenobiotic compounds and activates toxins [1–3] …
monooxygenase enzyme that metabolizes xenobiotic compounds and activates toxins [1–3] …
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19
SA Scott, K Sangkuhl, AR Shuldiner… - Pharmacogenetics …, 2012 - journals.lww.com
The cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) gene is located
within a cluster of cytochrome P450 genes (centromere-CYP2C18-CYP2C19-CYP2C9 …
within a cluster of cytochrome P450 genes (centromere-CYP2C18-CYP2C19-CYP2C9 …
PharmGKB summary: very important pharmacogene information for CYP3A5
J Lamba, JM Hebert, EG Schuetz… - Pharmacogenetics …, 2012 - journals.lww.com
The aim of a PharmGKB VIP summary is to provide a simple overview of a gene with respect
to drug effects. In some cases, there may be extensive evidence of variants that have known …
to drug effects. In some cases, there may be extensive evidence of variants that have known …
PharmGKB summary: very important pharmacogene information for CYP2B6
CYP2B6 is a member of the cytochrome P450 family of important pharmacogenes and
makes up approximately 2–10% of the total hepatic CYP content [1]. CYP2B6 is also …
makes up approximately 2–10% of the total hepatic CYP content [1]. CYP2B6 is also …
Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance
RA Totah, AE Rettie - Clinical Pharmacology & Therapeutics, 2005 - Wiley Online Library
Cytochrome P450 (CYP) 2C9 has been a relatively neglected member of the human CYP2C
family. Over the period from 2000 through 2003, PubMed searches with the key word …
family. Over the period from 2000 through 2003, PubMed searches with the key word …
Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapy
YB Jarrar, SJ Lee - Drug metabolism and drug interactions, 2014 - degruyter.com
Abstract CYP2C9 metabolizes approximately 20% of clinically used drugs, including the
narrow therapeutic window drugs warfarin and phenytoin. More than 16,000 variants have …
narrow therapeutic window drugs warfarin and phenytoin. More than 16,000 variants have …
Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development
SM He, ZW Zhou, XT Li, SF Zhou - Current medicinal chemistry, 2011 - ingentaconnect.com
CYP2C9 metabolizes more than 100 clinically used drugs including phenytoin, S-warfarin,
tolbutamide, glipizide, diclofenac, and losartan with varying contributions. CYP2C9 is …
tolbutamide, glipizide, diclofenac, and losartan with varying contributions. CYP2C9 is …
CYP2C9 allelic variants: ethnic distribution and functional significance
Cytochrome P-450 (CYP) 2C9 CYP2C9 is a polymorphically expressed enzyme responsible
for the metabolism of several clinically important drugs, some with a low therapeutic index …
for the metabolism of several clinically important drugs, some with a low therapeutic index …
PharmGKB summary: very important pharmacogene information for CYP1A2
Background CYP1A2 is part of the cytochrome P450 (CYP) family of drug-metabolizing
enzymes. The CYP1A2 gene is found in a cluster with CYP1A1 and CYP1B1 on …
enzymes. The CYP1A2 gene is found in a cluster with CYP1A1 and CYP1B1 on …